Last reviewed · How we verify
Metronidazole and Rifampin
Metronidazole and Rifampin is a Antibiotic combination Small molecule drug developed by McMaster University. It is currently in Phase 3 development for Polymicrobial infections or resistant anaerobic infections (Phase 3 investigational).
Metronidazole and rifampin are a combination of an antibiotic that disrupts bacterial DNA and an antibiotic that inhibits bacterial RNA polymerase, used together to treat infections resistant to single-agent therapy.
Metronidazole and rifampin are a combination of an antibiotic that disrupts bacterial DNA and an antibiotic that inhibits bacterial RNA polymerase, used together to treat infections resistant to single-agent therapy. Used for Polymicrobial infections or resistant anaerobic infections (Phase 3 investigational).
At a glance
| Generic name | Metronidazole and Rifampin |
|---|---|
| Sponsor | McMaster University |
| Drug class | Antibiotic combination |
| Target | Bacterial DNA (metronidazole); bacterial RNA polymerase (rifampin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Metronidazole is a nitroimidazole that generates reactive oxygen species and damages bacterial DNA, while rifampin inhibits bacterial RNA polymerase II, blocking transcription. The combination provides synergistic activity against anaerobic bacteria and certain aerobic pathogens, potentially overcoming resistance mechanisms and improving clinical outcomes in polymicrobial or difficult-to-treat infections.
Approved indications
- Polymicrobial infections or resistant anaerobic infections (Phase 3 investigational)
Common side effects
- Metallic taste
- Nausea
- Hepatotoxicity
- Peripheral neuropathy
- Drug interactions (rifampin enzyme induction)
Key clinical trials
- Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery (NA)
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients (PHASE3)
- Phenotyping of High Dose Rifampicin (PHASE1)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole and Rifampin CI brief — competitive landscape report
- Metronidazole and Rifampin updates RSS · CI watch RSS
- McMaster University portfolio CI
Frequently asked questions about Metronidazole and Rifampin
What is Metronidazole and Rifampin?
How does Metronidazole and Rifampin work?
What is Metronidazole and Rifampin used for?
Who makes Metronidazole and Rifampin?
What drug class is Metronidazole and Rifampin in?
What development phase is Metronidazole and Rifampin in?
What are the side effects of Metronidazole and Rifampin?
What does Metronidazole and Rifampin target?
Related
- Drug class: All Antibiotic combination drugs
- Target: All drugs targeting Bacterial DNA (metronidazole); bacterial RNA polymerase (rifampin)
- Manufacturer: McMaster University — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Polymicrobial infections or resistant anaerobic infections (Phase 3 investigational)